1. Home
  2. VSTS vs NVCR Comparison

VSTS vs NVCR Comparison

Compare VSTS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$9.25

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$12.19

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
NVCR
Founded
1936
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
VSTS
NVCR
Price
$9.25
$12.19
Analyst Decision
Sell
Buy
Analyst Count
4
6
Target Price
$5.88
$28.08
AVG Volume (30 Days)
997.5K
1.0M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
$2,734,839,000.00
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
$1.67
$6.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.28
52 Week Low
$3.98
$9.82
52 Week High
$9.80
$20.05

Technical Indicators

Market Signals
Indicator
VSTS
NVCR
Relative Strength Index (RSI) 75.88 57.94
Support Level $7.24 $10.72
Resistance Level $9.80 $13.78
Average True Range (ATR) 0.32 0.59
MACD 0.15 0.13
Stochastic Oscillator 97.47 91.54

Price Performance

Historical Comparison
VSTS
NVCR

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: